Возможности де-эскалации неоадъювантной терапии у больных с HER2-позитивным раком молочной железы changed the natural course of breast cancer. However, standard 
neoadjuvant chemotherapy regimens
 Sensitivity of multiple primary synchronous bilateral breast cancer to neoadjuvant chemotherapy) to 
neoadjuvant drug therapy. Subject and methods. The investigation enrolled 14 patients with multiple primary